Jane Street Group LLC Decreases Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Jane Street Group LLC lowered its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 79.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,437 shares of the biopharmaceutical company's stock after selling 132,994 shares during the quarter. Jane Street Group LLC owned about 0.05% of Xencor worth $814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after acquiring an additional 418,040 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Xencor by 2.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock valued at $92,758,000 after buying an additional 107,350 shares during the last quarter. TCG Crossover Management LLC raised its stake in Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC raised its stake in Xencor by 12.3% in the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after buying an additional 179,526 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Xencor by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company's stock valued at $34,509,000 after buying an additional 102,297 shares during the last quarter.

Insider Buying and Selling

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This trade represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.76% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on XNCR shares. Barclays decreased their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. William Blair started coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating for the company. Wedbush reiterated an "outperform" rating and issued a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. Wells Fargo & Company decreased their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Finally, Wall Street Zen cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $29.50.

Xencor Stock Performance

Shares of XNCR stock traded down $0.04 during mid-day trading on Wednesday, reaching $7.71. The stock had a trading volume of 286,416 shares, compared to its average volume of 655,634. The firm has a market cap of $548.87 million, a price-to-earnings ratio of -2.41 and a beta of 0.99. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The business's fifty day moving average is $9.45 and its 200-day moving average is $16.48. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm's revenue was up 104.6% on a year-over-year basis. During the same period last year, the business earned ($1.11) earnings per share. On average, research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.